Suppr超能文献

槲皮素预防和治疗化疗引起的口腔黏膜炎的随机安慰剂对照双盲临床试验

A Randomized Placebo- Controlled Double Blind Clinical Trial of Quercetin in the Prevention and Treatment of Chemotherapy-Induced Oral Mucositis.

作者信息

Kooshyar Mohammad Mahdi, Mozafari Pegah Mosannen, Amirchaghmaghi Maryam, Pakfetrat Atessa, Karoos Parisa, Mohasel Mahdokht Rashed, Orafai Hosein, Azarian Amir Abbas

机构信息

Associate Professor, Department of Hematology and Oncology, Imam Reza Hospital, Mashhad University of Medicals, Mashhad, Khorasan Razavi, Iran.

Associate Professor, Department of Oral and Maxillofacial Diseases Research Center, School of Dentistry, Mashhad University of Medical Sciences, Mashhad, Iran.

出版信息

J Clin Diagn Res. 2017 Mar;11(3):ZC46-ZC50. doi: 10.7860/JCDR/2017/23975.9571. Epub 2017 Mar 1.

Abstract

INTRODUCTION

Oral Mucositis (OM) is a serious complication of chemotherapy that results in painful debilitating inflammation that sometimes ends in interruption of treatment.

AIM

The study evaluated the effect of quercetin (a natural flavonoid) on preventing and treating chemotherapy induced OM in patients with blood malignancies. This double-blind, placebo controlled randomized trial was carried out on 20 adult patients who underwent high dose chemotherapy for blood malignancies. Patients were divided into two groups (10 patients in the intervention group and 10 patients in the control group). Patients in the intervention group were administered 250 mg quercetin capsules twice daily for four weeks.

RESULTS

Nine out of 20 patients developed OM (three in the intervention group and six in the control group). The incidence of OM was lower in the intervention group although it was not statistically significant (p=0.189). The mean severity of OM was higher in the intervention group (2.6 vs 2). Healing time, age, gender, type of malignancy, drug type and duration of OM were not different in two groups.

CONCLUSION

The incidence of mucositis was lower in the quercetin group, but mucositis was more severe in the intervention group, which may be due to lower oral health status in the intervention group.

摘要

引言

口腔黏膜炎(OM)是化疗的一种严重并发症,会导致疼痛性衰弱性炎症,有时会导致治疗中断。

目的

本研究评估了槲皮素(一种天然黄酮类化合物)对预防和治疗血液系统恶性肿瘤患者化疗所致口腔黏膜炎的效果。这项双盲、安慰剂对照随机试验对20名接受血液系统恶性肿瘤高剂量化疗的成年患者进行。患者分为两组(干预组10例,对照组10例)。干预组患者每天两次服用250毫克槲皮素胶囊,持续四周。

结果

20名患者中有9名发生口腔黏膜炎(干预组3名,对照组6名)。干预组口腔黏膜炎的发生率较低,尽管无统计学意义(p = 0.189)。干预组口腔黏膜炎的平均严重程度较高(2.6对2)。两组在愈合时间、年龄、性别、恶性肿瘤类型、药物类型和口腔黏膜炎持续时间方面无差异。

结论

槲皮素组黏膜炎的发生率较低,但干预组黏膜炎更严重,这可能是由于干预组口腔健康状况较差。

相似文献

引用本文的文献

3
Adjuvant Anti-tumor Therapy with Polyphenolic Compounds: A Review.多酚类化合物辅助抗肿瘤治疗:综述
Curr Med Chem. 2025;32(10):1934-1967. doi: 10.2174/0109298673284605240301035057.

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验